Ann: PAR achieves 100 per cent recruitment in Phase 2b OA Trial, page-18

Hey SottoVoce,

Prob best to do a little research or maybe stick to digging stuff out of the ground.
1) Elmiron (oral PPS) has, like, a less than 1% bioavailability so doesn't really get into the blood, therefore can't address inflammation in the joints but does stay in the bladder so great for inflammation of the bladder. Also ppl who have OA have got nothing else to treat them bar long term NSAIDs or Oxycontin so don't mind a few jabs, esp when it works. How do I know this? Cos I know some ppl who've been treated on the SAS program and they were in serious pain beforehand.
2) Looks like their BME project did become OA as BME is directly linked to OA and is widely considered to cause early onset of OA - read some of their announcements over the last year or so. Anyway what do I care OA is a much much much bigger market and it looks like they'll treating both injury BME and OA (maybe have a look at their presos)
3) the patents are Use Patents for repurposing - some famous repurposed drugs that you're no doubt familiar with are minoxidil, finasteride and viagra!

Yes I'm long this stock as I know a few ppl who've had it and the results are nothing short of remarkable and they've bought the stock as well, which is good enough for me!

As always DYOR and buckle up! Hope this has helped explain, plus def check the FiftyOne report.